Диссертация (1140752), страница 16
Текст из файла (страница 16)
дис. … канд. мед. наук. – М., 2009.40.Самсонова Н.Г., Звенигородская Л.А. Поджелудочная желез иметаболический синдром//Экспериментальная и клиническаягастроэнтерология.2011. —№11. — С.68 — 72.10441.Федосьина Е. А., Жаркова М. С., Маевская М. В. Бактериальная кишечнаямикрофлора и заболевания печени // Росс журн гастроэнтерол гепатолколопроктол 2009; 6:73-8142.Фадеева М.И., Савельева Л.В. Вторичное ожирение // Ожирение иметаболизм. 2014. —№1. — С.42 — 47.43.Черкашова Е.А. Метаболиты кишечной флоры и их значениев патогенезенеалкогольной жировой болезни печени и оценке гиполипидемическойтерапии: Дис. …кан.мед.
наук. . – М., 2011.44.Шибанова Е. И. Клинико-иммунологические аспектыинсулинорезистентности во время беременности //АГ-инфо. 2012. —№4. —С.20—27.45.Шифф Ю.Р., Соррел М.Ф., Мэддрей У.С. Вирусные гепатиты ихолестатические заболевания печени: руководство. Перевод с англ. / Подред. В.Т. Ивашкина, Е.А. Климовой, И.Г. Никитина, Е.Н. Широковой. М.:ГЭОТАР-Медиа, 2010.— 408с.46.Шифф Ю.Р., Соррел М.Ф., Мэддрей У.С Алкогольные, лекарственные,генетические и метаболические заболевания.
Перевод с англ./Под ред.Н.А.Мухина, Д.Т. Абдурахманова, Э.З.Бурневича, Т.Н. Лопаткиной, Е.Л.Танащук.М.: ГЭОТАР-Медиа, 2010. — 480с.47.Шифф Ю.Р., Соррел М.Ф., Мэддрей У.С Введение в гепатологию. Перевод сангл. / Под ред. В.Т. Ивашкина, А.О.
Буеверова ,М.В. Маевской.: М.:ГЭОТАР-Медиа, 2010. — 704с.48.Шилин Д.Е. Синдром гиперандрогении: современные подходы кдиагностике и новые технологии терапии // Лечащий врач. – 2003. – № 10. –С. 36-3949.Яковенко Э.П. Абдоминальный болевой синдром: этиология, патогенез ивопросы терапии // Клин. фармакол. тер. – 2002. – Т. 11, № 1.
– С. 24–27.50.Ярмолинская М.И., Савина В.А., Кветной И.М., Клещев М. А. Овариальнаяароматаза Р450 при синдроме поликистозных яичников // Медицинскийакадемический журнал. — 2012. — Том. 12. — вып. 1. — С. 47-53.10551.Angulo,P.Nonalcoholicfattyliverdisease // N.Engl.J.Med. — 2002. —№346. —Р.1221–1231.52.Anitha M., Vijay-Kumar M., Sitaraman S. V., Gewirtz A.
T., Srinivasan S. Gutmicrobial products regulate murine gastrointestinal motility via Toll-Like receptor4 signaling. Gastroenterology 2012; 143:1006- 16.53.AGA. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease:Practice Guideline by the American Gastroenterological Association, AmericanAssociation for the Study of Liver Diseases, and American College ofGastroenterology //Gastroenterology 2012. —№ 142. —Р.1592–160954.Aleksandrova MI, Kushnareva NS, Smirnova OV. Prolactine receptor expressionin kidney tissue of female rats with cholestasis: the effect of hyperprolactinemia //Bull Exp Biol Med.
– 2010–Vol.154, N 4– Р. 448-451.55. Alwis N.M., Day CP. Non-alcoholic fatty liver disease: the mist graduallyclears //J. Hepatol. – 2008. – Vol.48. –P.104–12.56.Assy N. et al. Fatty infiltration of liver in hyperlipidemic petients // Dig Dis Sci. –2010. –№45. –Р.1929-1934.57.Bae J.C. et al. Impact of nonalcoholic fatty liver disease on insulin resistance inrelation to HbA1c level in nondiabetic subjects //Am Jgastroenterology.
— 2010.—Vol. — 105. —P. 2389-2395.58.Baillie J. Sphincter of Oddi dysfunction// Curr. Gastroenterol. Rep. – 2010–Vol.12, N 2– Р. 130.59.Bahar A, Akha O, Kashi Z, Vesgari Z. Hyperprolactinemia in association withsubclinical hypothyroidism // Caspian J Intern Med. – 2011.— Vol 2. — № 2. —С.229-233.60.Barkun A.N., Love J., Gould M.
et al. Bile acid malabsorption in chronic diarrhea:pathophysiology and treatment // Can. J. Gastroenterol. – 2013. –Vol. 27 – N11. –Р. 690.61.Bedogni G. et al. Imcidence and natural course of fatty liver in the generalpopulation :the Dionys study //Hepatology. 2007. – № 46. –Р.1387-1391.62.Bell B.P., Manos M.M., Zaman A. The epidemiology of newly diagnosed chronicliver disease in gastroenterology practices in the United States: results from106population-based surveillance // Am. J. Gastroenterol.
– 2008 Nov. – Vol. 103, N11. – P. 2727–2736.63.Biddinger S.B., Haas J.T. et ol. Hepatic insulin resistance directly promotesformation of cholesterol gallstones // Nat Med. – 2008. – Vol. 14. –Р. 778-782.64.Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut1985. – № 26. – P. 133–139.65.Browning J.D. Et al. Prevalence of hepatic steatosis in an urban population in theUnited states: impact of ethnicity //Hepatology 2004.
– № 40. – Р.1387-1395.66.Cabarellia L et. Al. Prevalence and factors associated with the presence of nonakcoholic liver disease in adult population in Spain //Eur J Gastroenterol. Hepatol.– 2010. – №22. – Р.24-32.67.Carbone L.J., Angus P.W., Yeomans N.D. Incretin-based therapies for thetreatment of nonalcoholic fatty liver disease: A systematic review and metaanalysis//Journal of Gastroenterology and Hepatology68.Chambel S.S., Santos-Gonçalves A., Duarte T.L. The Dual Role of Nrf2 inNonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses andHepatic Lipid Metabolism // BioMed Research International. – 2015, Article ID597134.69.Chang Y., Sung E., Ryu S.
et ol. Insulin resistance is associated with gallstoneseven in non-obese, non-diabetic Korean men // J. Korean Med Sci. – 2008. – Vol.28. – P.935-947.70.Cheung O., Sanyal A.J. Recent Advances in Nonalcoholic Fatty Liver Disease:Pathogenesis // Curr Opin Gastroenterol. – 2010. –Vol. 26. – №3. – Р.202–208.71.Chi-Ming Liu, Chung-Te Hsu, Chung-Yi Li.
A population-based cohort study ofsymptomatic gallstone disease in diabetic patients// World J Gastroenterol. –2012. – Vol. 18. –№14. – P.1652 –1659.72.Cojocaru C, Pandele GI. Metabolic profile of patients with cholesterol gallstonedisease//Rev Med Chir Soc Med Nat Iasi.
– 2010. – Vol. 114. – №3. – Р.677682.73.Delgado-Aros S., Locke G. R. 3rd, Camilleri M., Talley N. J., Fett S., ZinsmeisterA. R., Melton L. J. 3rd. Obesity is associated with increased risk of107gastrointestinal symptoms: a population-based study// Am J Gastroenterol 2004;99:1801-6.74.Diamanti-Kandarakis Е., Dunaif А. Insulin Resistance and the Polycystic OvarySyndrome Revisited: An Update on Mechanisms and Implications // EndocrineReviews. – 2012.
– Vol. 33, №6. –Р.981–1030.75.Dzhulaĭ GS, Bazhenov DV, Chervinets VM, Mikhaĭlova ES, L'vova MA.Morphological features and esophago-gastroduodenal zone microbiocenose inpatients with syndrome postcholecystectomic syndrome // Eksp KlinGastroenterol. – 2011. –№9. – Р.30-35.76.Emokpae MA, Osadolor HB, Omole Ohonsi A. Sub-clinical hypothyroidism ininfertile Nigerian women with hyperprolactinaemia // Niger J Physiol Sci. – 2011.– Vol. 23. – №26(1). – Р.35-38.77.Everhart J.E., Ruhl C.E. et ol. Association of diabetes, serum insulin, and Cpeptide with gallbladder disease // Hepatology.
– 2000. – №31. – P. 299–303.78. Festi D, Dormi A., Capodicasa S. et ol. Incidence of gallstone disease in Italy:Results from a multicenter, population-based Italian study (the MICOL project) //World J Gastroenterol. – 2000. – Vol 14. – №14. – P.5282-5289.79.Feng-Lin Liu, Wen-Bin Lu, and Wei-Xin Niu. XbaI polymorphisms ofapolipoprotein B gene: Another risk factor of gallstone formation after radicalgastrectomy //World J Gastroenterol.
May 28. doi: 10.3748/wjg.v16.i20.254980.Florentino GS. Et al. Nonalcoholic fatty liver disease in menopausal women // Arggastroenterol. – 2013. – Vol. 50. – №3. – Р.180-185.81.Fracanzani AL, Valenti L, Russello M. et ol. Gallstone disease is associated withmore severe liver damage in patients with non-alcoholic fatty liver disease. PLoSOne. – 2012;7(7):e41183. doi: 10.1371/journal.pone.0041183. Epub 2012 Jul 25.82.Frith J et al. Non-alcoholic fatty liver disease in older people. Gerontology. –2009.–Vol. 55.
– №6. – 607-613.83.García-Monzón C, Vargas-Castrillón J, Porrero JL. Prevalence and risk factors forbiopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis108in a prospective cohort of adult patients with gallstones //Liver international.
–2015. Feb 24. doi: 10.1111/liv.12813.84.Gastaldelli A., Kozakova M., Hojlund K. et al. Fatty liver is associated withinsulin resistance, risk of coronary heart disease, and early atherosclerosis in alarge European population //Hepatology. –2009. – №49. – Р.1537–1544.85.Gavaler J.S., Van Thiel D.H., Deal S.R. Surgical risk in alcoholic cirrhoticpostmenopausal women: prognostic value of levels of hormones // J Surg OncolSuppl.
– 1993. – №.3 – P.52-54.86.Gonzales P.H., Rhoden C.R., Luz C., Corrêa G., Barbosa-Coutinho L.M., OliveiraM.C.. Male gonadal function, prolactin secretion and lactotroph population in anexperimental model of cirrhosis // Braz J Med Biol Res. – 2007. – Vol. 40. – №10. – P. 1383-1388.87.Grandison GA, Angulo P. Can NASH be diagnosed, graded, and stagednoninvasively // Clin Liver Dis . – 2012.
– Vol. 16. – №3. – Р.567-585.88.Hamaguchi M. et al. The metabolic syndrome as a predictor of non-alcoholic fattyliver disease // Ann Inter Med. – 2005. – Vol.143. – №10. – 722-728.89.Haring et al. Ultrasonografic hepatic steatosis increases prediction of mortalityrisk from elevated swrum gamma-glutamyl transpeptidase levels // Hepatology. –2009. – №50. –Р.1403-1411.90.Hossein Ajdarkosh, Mohammad Reza Khansari, Masoud Reza Sohrabi et ol.Thyroid Dysfunction and Choleduocholithiasis // Middle East J Dig Dis. – 2013. –Vol.
7. – №5(3). – 141–145.91.Huang S.M., Yao C.C., Pan H., Hsiao K.M., Yu J.K., Lai T.J., Huang S.D. et ol.Pathophysiological significance of gallbladder volume changes in gallstonediseases // World J Gastroenterol. – 2010. – Vol. 16, № 34. – P.4341- 4347.92.Hui Sun, Hong Tang, Shan Jiang et ol. Gender and metabolic differences ofgallstone diseases //World J Gastroenterol.
– 2009. – Vol. 15, № 34. – P. 1886–1891.10993.Igal R.A., de Gómez Dumm I.N., Goya R.G. Modulation of rat liver lipidmetabolism by prolactin // Prostaglandins Leukot Essent Fatty Acids. – 1998. –Vol. 59. – N 6. – Р.395-40094.Jaunoo S. S., Mohandas S., Almond L.M. Postcholecystectomy syndrome (PCS) //Int. J. Surg. – 2010. – Vol. 8. – N 1.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
